| Autor: |
Torretta, Lorella, Perotti, Cesare, Pedrazzoli, Paolo, Dornini, Gianluca, Viarengo, Gianluca, Livraghi, Alessandra, Noris, Patrizia, Prada, Gian Antonio Da, Balduini, Carlo L., Cuna, Gioacchino Robustelli della, Salvaneschi, Laura |
| Zdroj: |
Vox Sanguinis; November 1998, Vol. 75 Issue: 3 p224-229, 6p |
| Abstrakt: |
Objectives: The use of circulating progenitor cell support following high-dose chemotherapy for malignancies decreases but does not entirely abolish platelet transfusion requirement. We investigated the feasibility of supporting the posttransplant thrombocytopenic phase exclusively with autologous platelets collected by apheresis and cryopreserved. Methods: 25 patients underwent plateletpheresis during the platelet rebound occurring after high-dose cyclophosphamide. Autologous platelets were cryopreserved in 5% dimethylsulfoxide, thawed and transfused during the aplastic phase after the myeloablative regimen whenever clinically required. Results: A single plateletpheresis was carried out in all patients, allowing the harvest of a platelet concentrate with a mean value of 7.7 × 10 11 platelets. No significant procedure- or transfusion-related side effects were recorded. Mean platelet recovery after freezing and thawing was 63% and the mean number of platelet reinfused was 4.8 × 1011; 23 of 25 patients were fully supported with autologous platelets. Conclusion: Plateletpheresis performed in our selected group of patients was found to be a safe and effective procedure to collect large amounts of autologous platelets; the numbers obtained proved to be sufficient for the transfusion demand of almost all patients. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text